****

**Copyright Information of the Article Published Online**

|  |  |
| --- | --- |
| **TITLE** | Update on medical and surgical options for patients with acute severe ulcerative colitis: what is new? |
| **AUTHOR(s)** | Rachel E Andrew, Evangelos Messaris |
| CITATION | Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: what is new? World J Gastrointest Surg 2016; 8(9): 598-605 |
| URL | http://www.wjgnet.com/1948-9366/full/v8/i9/598.htm |
| DOI | http://dx.doi.org/10.4240/wjgs.v8.i9.598 |
| OPEN ACCESS | This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| CORE TIP | The numerous avenues of medical and sur-gical therapy have allowed for great advances in the treatment of patients with ulcerative colitis. In this era of options, it is important to maintain a global view, utilize corticosteroids and rescue therapy when indicated, and then maintain an appropriate threshold for surgery. Colectomy remains a viable and often life-saving treat-ment and should not be viewed as the “therapy of last resort”. |
| KEY WORDS | Acute severe ulcerative colitis; colectomy; corticosteroids; infliximab; cyclosporine; ileal pouch-anal anastomosis |
| COPYRIGHT  | **© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved. |
| NAME OF JOURNAL | World Journal of Gastrointestinal Surgery |
| ISSN | 1948-9366 (online) |
| PUBLISHER | Baishideng Publishing Group Inc, 8226 Regency Drive, Pleasanton, CA 94588, USA |
| WEBSITE | http://www.wjgnet.com |

MINIREVIEWS

Update on medical and surgical options for patients with acute severe ulcerative colitis: what is new?

Rachel E Andrew, Evangelos Messaris

Rachel E Andrew, Evangelos Messaris,Department of Surgery, College of Medicine, the Pennsylvania State University, Hershey, PA 17033-0850, United States

Author contributions: Andrew RE acquired and analyzed the data, and drafted the manuscript; Andrew RE and Messaris E designed the study, interpreted the data and critically revised the manuscript for important intellectual content; Messaris E supervised the study.

Correspondence to:Rachel E Andrew, MD, Department of Surgery, College of Medicine, the Pennsylvania State University, 500 University Drive, Hershey, PA 17033-0850, United States. randrew@hmc.psu.edu

Telephone:+1-717-5315164 Fax:+1-717-5310646

Received:March 29, 2016Revised:July 14, 2016Accepted:July 29, 2016

Published online: September 27, 2016

**Abstract**

Acute severe ulcerative colitis (UC) is a highly morbid con­dition that requires both medical and surgical management through the collaboration of gastroenterologists and colorectal surgeons.First line treatment for patients presenting with acute severe UC consists of intravenous steroids, but those who do not respond require escalation of therapy or emergent colectomy. The mortality of emergent colectomy has declined significantly in recent decades, but due to the morbidity of this procedure, second line agents such as cyclosporine and infliximab have been used as salvage therapy in an attempt to avoid emergent surgery. Unfortunately, protracted medical therapy has led to patients presenting for surgery in a poorer state of health leading to poorer post-operative outcomes. In this era of multiple medical modalities available in the treatment of acute severe UC, physicians must consider the advantages and disadvantages of prolonged medical therapy in an attempt to avoid surgery. Colectomy remains a mainstay in the treatment of severe ulcerative colitis not responsive to corticosteroids and rescue therapy, and timely referral for surgery allows for improved post-operative outcomes with lower risk of sepsis and improved patient survival. Options for reconstructive surgery include three-stage ileal pouch-anal anastomosis or a modified two-stage procedure that can be performed either open or laparoscopically. The numerous avenues of medical and surgical therapy have allowed for great advances in the treatment of patients with UC. In this era of options, it is important to maintain a global view, utilize biologic therapy when indicated, and then maintain an appropriate threshold for surgery. The purpose of this review is to summarize the growing number of medical and surgical options available in the treatment of acute, severe UC.

**Key words:** Acute severe ulcerative colitis; colectomy; corticosteroids; infliximab; cyclosporine; ileal pouch-anal anastomosis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

Andrew RE, Messaris E.Update on medical and surgical options for patients with acute severe ulcerative colitis: what is new? *World J Gastrointest Surg* 2016; 8(9): 598-605 Available from: URL: http://www.wjgnet.com/1948-9366/full/v8/i9/598.htm DOI: http://dx.doi.org/10.4240/wjgs.v8.i9.598

**Core tip:** The numerous avenues of medical and sur­gical therapy have allowed for great advances in the treatment of patients with ulcerative colitis. In this era of options, it is important to maintain a global view, utilize corticosteroids and rescue therapy when indicated, and then maintain an appropriate threshold for surgery. Colectomy remains a viable and often life-saving treat­ment and should not be viewed as the “therapy of last resort”.

**INTRODUCTION**

Acute severe ulcerative colitis (UC) is an exacerbation of a chronic condition characterized by inflammation of the colonic mucosa extending from the rectum proximally to varying portions of the large intestine. UC is a highly morbid condition that requires both medical and surgical management. Prior to the 1950’s and the implementation of urgent colectomy and systemic steroids, mortality rates were as high as 70% in patients with severe UC[1]. In recent years, mortality rates have dropped to less than 1% with the combination of medical therapy, rescue therapy, and timely total abdominal colectomy (TAC) when indicated[2,3]. Despite the introduction of rescue therapies such as cyclosporine (calcineurin inhibitor) and infliximab [tumor necrosis factor (TNF) monoclonal anti­body] in the treatment regimen of patients with severe UC, colectomy rates have remained stable (27%) for the past thirty years[4].

Historically, severe UC has been defined as the passage of at least six daily bloody stools, along with any of the following signs of systemic disease: Erythrocyte sedimentation rate > 30 mm/h, temperature > 37.8 ℃, pulse rate > 90/min and hemoglobin < 10.5 g/dL (true­love and witts criteria)[5]. Lichtiger created a scoring system for severe UC based on frequency of stools, nocturnal diarrhea, blood in stool, fecal incontinence, and abdominal pain[6]. These criteria play a significant role in the decision to escalate therapy or proceed to colectomy in patients with severe disease. Rates of TAC within the first five years of disease range from 9%-35%, even with medical therapy[7]. With a growing number of options available to both gastroenterologists and surgeons in the management of UC, treatment is becoming more individualized and variable. The following review provides a description of current medical and surgical management of acute severe UC.

**STANDARD MEDICAL THERAPY**

Patients presenting with signs of acute severe UC require immediate admission to the hospital. They must have regular monitoring of vital signs and urine output as well as a comprehensive laboratory workup. Initial tests on admission should include a comprehensive metabolic panel, pre-albumin, albumin, complete blood count, and inflammatory markers [erythrocyte sedimentation rate and C-reactive protein (CRP)][5]. A tuberculin skin test should also be performed on that admission in preparation for possible treatment with immunosuppressant or bio­logic agents. Abdominal imaging should be obtained to evaluate for colonic dilation (greater than 5.5 cm) on plain X-ray or computed tomography scan, and the patient should be monitored for fever, leukocytosis and other signs of systemic sepsis that accompany toxic megacolon[8,9].

Stool cultures and a clostridium difficile assay must be obtained to exclude infectious pseudomembranous colitis, and the frequency and consistency of bowel movements should be recorded.

Patients should take nothing by mouth and should be fluid resuscitated to a goal of 0.5 mL/kg per hour of urine output. The administration of intravenous fluids and the correction of electrolyte imbalances prevent dehydration and worsening of colonic dysmotility and dilatation[10]. All patients who are not bleeding should be given thromboembolic prophylaxis due to the increased risk of thrombosis in the setting of systemic inflammation. In addition, the patient should undergo flexible sig­moidoscopy to confirm the diagnosis of acute severe UC and to obtain biopsies to rule out cytomegalovirus colitis[11].

Patients with acute severe UC require constant reas­sessment, with antibiotic administration in the setting of infection, total parenteral nutrition in the setting of malnutrition, and escalation of therapy to medication non-responders. Kedia *et al*[12] proposed an algorithm for reassessing patient steroid response at days 1, 3 and 4-7 in which incomplete responders and non-responders either advance to rescue therapy or proceed to colectomy. In this algorithm, the Oxford criteria (> 8 stools/d or > 3 stools/d with a CRP > 45 mg/L) are used to determine the need for escala­tion of therapy[13]. With careful attention to the patient’s physical condition and severity of illness, the appropriate medical or surgical therapy can be selected to target the individual’s ever-changing disease (Figure 1).

**CORTICOSTEROIDS**

Corticosteroids were introduced in the management of UC in the 1950’s, though the first clinical trial proving their efficacy was not published until the 1970’s[5,14]. For the past 40 years, intravenous corticosteroids (methy­lprednisolone 60 mg/d or hydrocortisone 100 mg/8 h) for a 7-10 d course have been a cornerstone in the treat­ment of acute severe UC[4,14]. A large review and meta-analysis reported the response to IV steroids to be 67% with short term colectomy rate of 29%[4].

**MEDICAL RESCUE THERAPY**

Rescue therapies made their first appearance in the medical management of UC in the 1990’s with the intro­duction of cyclosporine. Infliximab followed soon after as an alternative therapy with a different side-effect profile that could also serve as a salvage therapy in the setting of UC refractory to corticosteroids.

Cyclosporine (2-4 mg/kg) has been shown to induce remission in 60%-80% of patients with acute severe colitis, but colectomy rates at four months remain close to 50% unless the patient is successfully bridged to maintenance therapy[6,15,16]. The role of infliximab in the treatment of non-acute, moderate-to-severe UC has been reported in the Active Ulcerative Colitis Trials 1 and 2, with response rates between 61% and 69%[17]. Infliximab (5 mg/kg) has also been shown to significantly decrease rate of colectomy at three months for patients with severe to moderate attacks of UC[18]. In an Italian trial by Kohn *et al*[19] there was an 85% response rate to infliximab with no colectomy in the 2 mo following hospital admission for acute severe UC and 67% at 23 mo. Multiple studies have compared infliximab and cyclosporine as rescue therapy for acute severe UC with no significant difference between the two therapies. Colectomy rates were similar at three and twelve months between patients receiving infliximab (31% and 41%) and cyclosporine (30% and 44%)[20,21]. A recent systematic review and meta-analysis compared infliximab and cyclosporine as rescue therapy and found no significant difference in 3 or 12 mo colectomy rates among three randomized trials but reported significantly increased response to treatment and lower 12 mo colectomy rate among 12 non-randomized studies[22].

While immunosuppressant and biologic agents have become established means of treating severe UC, there is conflicting evidence on the use of sequential therapy. Reports of the use of infliximab after failing steroids and cyclosporine have shown a 30% colectomy rate[23]. A review of 10 studies in which rescue therapies were used sequentially for treatment of acute severe UC demonstrated colectomy rates of 28% at 3 mo and 42% at 12 mo with a 23% rate of adverse events-lower than previously reported in the literature[24]. At this time, the selection of a rescue therapy agent, cyclosporine *vs* infliximab *vs* one agent following the other, is based primarily on physician comfort and experience, along with patient tolerance of side effects and susceptibility to infection.

**IMMUNOMODULATORS**

Although not currently the standard of care, vedolizumab, an integrin antibody, has been shown to induce steroid-free remission in approximately one third of UC patients who have failed anti-TNF therapy[25]. Further investigation is required before recommendations can be made for its use in the treatment of acute severe UC.

Other agents such as thiopurines and methotrexate play a role in maintenance therapy and steroid dose reduction, but these drugs have shown no significant success as induction therapy to achieve remission in patients with active UC[26,27].

**Antibiotics**

The role of antibiotics in the treatment of acute severe UC remains limited because even in severe UC there is no proven therapeutic benefit to oral or intrave­nous metronidazole, tobramycin, ciprofloxacin or vanco­mycin[28-30]. Only in the setting of active infection or for pre-operative antibiotic prophylaxis do 2012 ECCO guidelines recommend that antibiotics be administered[31].

**SURGICAL THERAPY**

Although tremendous advances have been made in the medical treatment of UC, colectomy remains a corner­stone in the management of this disease. Overall, the rates of colectomy have not significantly changed since the addition of rescue therapies to the armamenta­rium of gastroenterologists. Predictors of the need for second-line treatment or colectomy are numerous, but several variables, including severity of disease, stool frequency, CRP, hyopoalbuminemia (< 3 mg/dL), and radiographic evidence of colonic dilation (> 5.5 cm), all can be used in early identifica­tion of the need for escalation of therapy[32-34]. A more recent scoring system also includes the need for blood transfusions or parenteral nutrition as predictors of need for colectomy[35].

**COLECTOMY AFTER MEDICAL RESCUE THERAPY**

Due to the growing number of medical therapies for severe UC, patients are being referred for colectomy later after multiple attempts at medical salvage. These patients present in a poorer state of health, malnourished and anemic, and the delay is not without consequences.

Patients who undergo an operation after receiving high dose steroids or who are malnourished often have increased surgical complications[36]. Post-operative com­plications include anastomotic leak, stricture, fistulae, and bowel obstruction. One study reported the rate of post-operative complications to be over three times higher, with the rate of sepsis being 13 times higher, in patients undergoing three-stage ileal pouch-anal anastomosis (IPAA) after treatment with infliximab[37]. Similarly, signi­ficantly higher rates of major complications were found in patients undergoing longer duration of medical therapy (> 8 d) in a group of 80 patients with severe UC followed over the course of 7 years[13].

The importance of continuous reassessment of the need for surgery is emphasized due to the mortality benefits of a well-timed or elective operation; mortality rates three years after elective colectomy (3.7%) are significantly lower than after admission without surgery (13.6%) or with emergent surgery (13.2%) in patients with acute severe UC[38].

**STAGED APPROACH**

Surgical management of UC in the setting of failed me­dical therapy involves the performance of a TAC with an optional IPAA in two or three stages[3]. In a three-stage approach, the initial operation involves a subtotal or TAC with creation of an end ileostomy. The stapled or hand-sewn rectosigmoid stump can be sutured as a mucous fistula to the distal aspect of the abdominal wall incision, may be closed and sutured to the subcutaneous tissue, or may be left unattached in the pelvis. The primary reason for creation of a mucous fistula or placement of the long rectal stump in the subcutaneous tissue is to avoid rectal stump breakdown and leakage with subsequent pelvic sepsis, especially in cases of severe inflammation and thickening of tissue[39]. The drawback to a mucous fistula lies in patient dissatisfaction that may occur with persistent discharge during the long-term recovery period[40]. The manner in which the rectosigmoid is closed depends mainly upon patient anatomy and surgeon preference, but transanal rectal decompression is commonly performed following all techniques[3]. TAC with end ileostomy as the first stage allows for immediate diversion of the fecal stream, avoids the dangers of a pelvic dissection or anastomosis in a critically ill patient, and allows for preservation of the rectum with the possible diagnosis of Crohn’s colitis rather than UC.

The second stage of the procedure involves pouch formation with diverting ileostomy. Restorative procto–colectomy with IPAA is an elective operation performed in the absence of toxicity or severe malnutrition. Although proximal diversion does not prevent pelvic sepsis in the setting of IPAA, diverting ileostomy has been shown to lessen complications related to anastomotic leakage[41,42]. The procedure can be technically challenging and involves identification of the rectal stump with full mobilization to the level of the levator ani muscles, proctectomy, and construction of a J-shaped pouch through a side-to-side anastomosis of the distal 40 cm of terminal ileum[43]. Although several pouch designs have been promoted over the years, including the S-pouch and the W-pouch, the J-pouch has endured due to its relatively simple con­struction and equivalent or superior outcomes to other designs[43,44]. The IPAA may be stapled or hand-sewn but fewer complications and better long-term quality of life have been reported in patients undergoing stapled anastomosis[45].

The third stage of the procedure involves takedown of the diverting ileostomy and reestablishment of intestinal continuity. This final step should only be performed after water-soluble contrast enema has demonstrated patency and anastomotic integrity of the pouch.

In rare cases (5%), patients present with rectal sparing disease, and TAC with end ileostomy remains the first step to patient recovery[46]. Only in these specific cases has ileorectal anastomosis as an alternative to pouch formation been described for reconstruction of the gastrointestinal tract[47].

Although colectomy and pouch formation may be and are routinely performed as one procedure, this operation is reserved for UC patients who are healthy, well-nourished, off steroids and not experiencing an acute flare[41]. Performing a three stage procedure allows for healthier, better nourished patients at the time of surgery[48]. Some centers have attempted to abbreviate the hospital course of acute severe UC pati­ents by per­forming a modified two-stage procedure (colectomy followed by IPAA and ileostomy takedown). Zittan *et al*[49] demonstrated significantly lower rates of anastomotic leak (4.6% *vs* 15.7%) when comparing modified 2-stage IPAA to the traditional 2-stage procedure (colectomy with pouch formation followed by ileostomy takedown). Swenson *et al*[50] demonstrated equivalent patient outcomes with significantly lower hospital cost in patients with resolved severe colitis after colectomy who underwent a modified two-stage IPAA *vs* a three-stage procedure. The cost of medical therapy is not only affected by the operation performed but also by the timing of the procedure. In a comparison of patients with severe UC undergoing early colectomy with IPAA *vs* standard medical therapy, Park *et al*[51] reported a cost analysis showing a $90000 increase in cost to patients who received prolonged medical salvage therapy with very little improvement in quality of life.

**ROLE OF LAPAROSCOPY**

A laparoscopic approach to TAC in severe UC patients provides a reasonable alternative to the open approach and has been shown to be equally safe and feasible in comparison[52]. While the laparoscopic approach has the advantage of reducing post-operative pain, time to stoma function, and overall hospital stay, it also leads to longer operative time and may be more technically demanding for the surgeon[53,54].

**LONG-TERM OUTCOMES OF IPAA**

Although the ileal pouch does allow many patients to have a more normal life-style and defecation pattern, the procedure is not without enduring consequences. A recent study from the Cleveland Clinic published long-term outcomes of 74 patients who underwent IPAA and were followed over a 20-year period. Pouch-specific compli­cations included pouchitis (45%), stricture (16%), fistula (30%), obstruction (20%), and change of diagnosis to Crohn’s (28%). Long-term consequences of the pro­cedure also included frequent stooling requiring anti-diarrheal medication (44%) and difficulty conceiving (25% and all women)[44]. Pouch failure rates at 10 and 20 years have been reported to be 9% and 14%, although a 2016 study reported a failure rate of 2.4%, indicating that pouch outcomes may be improving[44,55,56]. The three stage approach with proximal diversion may be asso­ciated with better outcomes as it reduces the impact that complications such as pelvic sepsis or anastomotic leak have on the ultimate quality of the pouch[41].

While a substantial number of UC patients do elect to undergo IPAA after TAC, this procedure is not man­datory, and many choose to forgo the pouch completely. A Swedish cohort study of over 2000 patients who underwent colectomy for inflammatory bowel disease showed that less than half (43%) of the patients under­went reconstructive surgery over a ten year period[57]. A 2015 review of UC patients with an end ileostomy or IPAA demonstrated equivalent improvement in quality of life at 1 year with the majority of the benefit related to the control of disease symptoms[58].

**CONCLUSION**

The optimal treatment algorithm in the management of severe UC remains controversial. The purpose of this review is to summarize the current medical and surgical options available in the treatment of acute, severe UC.

First line treatment for patients presenting with acute severe UC consists of intravenous steroids, but those who do not respond require escalation of therapy or emergent colectomy. The mortality of emergent colectomy has declined significantly in recent decades, but due to the morbidity of this procedure, second line agents such as cyclosporine and infliximab have been used as rescue therapy in an attempt to avoid emergent surgery. In this era of multiple medical modalities available in the treatment of acute severe UC, it is imperative that physicians consider the advantages and disadvantages of prolonged medical therapy in an attempt to avoid surgery. Colectomy remains a mainstay in the treatment of severe ulcerative colitis not responsive to cortico­steroids and rescue therapy, and timely referral for surgery allows for improved post-operative outcomes with lower risk of sepsis and improved patient survival.

Options for reconstructive surgery include three-stage IPAA or a modified two-stage procedure. The three-stage procedure offers the advantage of a healthier, well-nourished patient, but the two-stage procedure offers fewer in-hospital days and decreased overall cost.

The numerous avenues of medical and surgical the­rapy have allowed for great advances in the treatment of patients with UC. In this era of options, it is important to maintain a global view, utilize rescue therapy when indicated, and then maintain an appropriate threshold for surgery. Colectomy remains a viable and often life-saving treatment and should not be viewed as the “therapy of last resort”.

**ACKNOWLEDGMENTS**

We would like to acknowledge Lisa McCully, Projects Specialist, for her assistance in designing Figure 1.

**REFERENCES**

1 **Hardy TL**, Bulmer E. Ulcerative Colitis: A Survey of Ninety-five Cases. *Br Med J* 1933; **2**: 812-815 [PMID: 20777868 DOI: 10.1136/bmj.2.3800.812]

2 **Dayan B**, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. *World J Gastroenterol* 2012; **18**: 3833-3838 [PMID: 22876035 DOI: 10.3748/wjg.v18.i29.3833]

3 **Brown SR**, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. *Colorectal Dis* 2008; **10** Suppl 3: 8-29 [PMID: 18954307 DOI: 10.1111/j.1463-1318.2008.01682.x]

4 **Turner D**, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. *Clin Gastroenterol Hepatol* 2007; **5**: 103-110 [PMID: 17142106 DOI: 10.1016/j.cgh.2006.09.033]

5 **Truelove SC**, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955; **2**: 1041-1048 [PMID: 13260656 DOI: 10.1136/bmj.2.4947.1041]

6 **Lichtiger S**, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med* 1994; **330**: 1841-1845 [PMID: 8196726 DOI: 10.1056/NEJM199406303302601]

7 **Langholz E**, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. *Gastro­enterology* 1992; **103**: 1444-1451 [PMID: 1358741 DOI: 10.1016/0016-5085(92)91163-X]

8 **Trudel JL**, Deschênes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. *Dis Colon Rectum* 1995; **38**: 1033-1038 [PMID: 7555415 DOI: 10.1007/BF02133974]

9 **Seah D**, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. *Aliment Pharmacol Ther* 2016; **43**: 482-513 [PMID: 26725569 DOI: 10.1111/apt.13491]

10 **Gan SI**, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. *Am J Gastroenterol* 2003; **98**: 2363-2371 [PMID: 14638335 DOI: 10.1111/j.1572-0241.2003.07696.x]

11 **Criscuoli V**, Casà A, Orlando A, Pecoraro G, Oliva L, Traina M, Rizzo A, Cottone M. Severe acute colitis associated with CMV: a prevalence study. *Dig Liver Dis* 2004; **36**: 818-820 [PMID: 15646428 DOI: 10.1016/j.dld.2004.05.013]

12 **Kedia S**, Ahuja V, Tandon R. Management of acute severe ulcera­tive colitis. *World J Gastrointest Pathophysiol* 2014; **5**: 579-588 [PMID: 25401001 DOI: 10.4291/wjgp.v5.i4.579]

13 **Randall J**, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. *Br J Surg* 2010; **97**: 404-409 [PMID: 20101648 DOI: 10.1002/bjs.6874]

14 **Truelove SC**, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. *Lancet* 1974; **1**: 1067-1070 [PMID: 4135487]

15 **Cheifetz AS**, Stern J, Garud S, Goldstein E, Malter L, Moss AC, Present DH. Cyclosporine is safe and effective in patients with severe ulcerative colitis. *J Clin Gastroenterol* 2011; **45**: 107-112 [PMID: 20679905 DOI: 10.1097/MCG.0b013e3181e883dd]

16 **Fornaro R**, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovi­nazzo D, Sticchi C, Caratto E. Surgical and medical treatment in patients with acute severe ulcerative colitis. *J Dig Dis* 2015; **16**: 558-567 [PMID: 26315728 DOI: 10.1111/1751-2980.12278]

17 **Rutgeerts P**, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005; **353**: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]

18 **Järnerot G**, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H, Hellström PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. *Gastroenterology* 2005; **128**: 1805-1811 [PMID: 15940615 DOI: 10.1053/j.gastro.2005.03.003]

19 **Kohn A**, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G, Marrollo M, Sostegni R, Gasbarrini A, Peralta S, Prantera C. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. *Aliment Pharmacol Ther* 2007; **26**: 747-756 [PMID: 17697208 DOI: 10.1111/j.1365-2036.2007.03415.x]

20 **Chang KH**, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. *Int J Colorectal Dis* 2013; **28**: 287-293 [PMID: 23114475 DOI: 10.1007/s00384-012-1602-8]

21 **Croft A**, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. *Aliment Pharmacol Ther* 2013; **38**: 294-302 [PMID: 23786158 DOI: 10.1111/apt.12375]

22 **Narula N**, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. *Am J Gastroenterol* 2016; **111**: 477-491 [PMID: 26856754 DOI: 10.1038/ajg.2016.7]

23 **Chaparro M**, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Senent SG, Gomollón F, Calvet X, García-Planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Nyssen OP, Gisbert JP. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. *Aliment Pharmacol Ther* 2012; **35**: 275-283 [PMID: 22142227 DOI: 10.1111/j.1365-2036.2011.04934.x]

24 **Narula N**, Fine M, Colombel JF, Marshall JK, Reinisch W. Systematic Review: Sequential Rescue Therapy in Severe Ulcera­tive Colitis: Do the Benefits Outweigh the Risks? *Inflamm Bowel Dis* 2015; **21**: 1683-1694 [PMID: 25839775 DOI: 10.1097/MIB. 0000000000000350]

25 **Amiot A**, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group and the Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol* 2016; Epub aheaad of print [PMID: 26917043 DOI: 10.1016/j.cgh.2016.02.016]

26 **Khan HM**, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. *Clin Exp Gastroenterol* 2015; **8**: 293-302 [PMID: 26648749 DOI: 10.2147/CEG.S57248]

27 **Bressler B**, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. *Gastroenterology* 2015; **148**: 1035-1058.e3 [PMID: 25747596 DOI: 10.1053/j.gastro. 2015.03.001]

28 **Chapman RW**, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. *Gut* 1986; **27**: 1210-1212 [PMID: 3536677]

29 **Nitzan O**, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. *World J Gastroenterol* 2016; **22**: 1078-1087 [PMID: 26811648 DOI: 10.3748/wjg.v22.i3.1078]

30 **Khan KJ**, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol* 2011; **106**: 661-673 [PMID: 21407187 DOI: 10.1038/ajg.2011.72]

31 **Dignass A**, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 2012; **6**: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]

32 **Ho GT**, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, Satsangi J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. *Aliment Pharmacol Ther* 2004; **19**: 1079-1087 [PMID: 15142197 DOI: 10.1111/j.1365-2036.2004.01945.x]

33 **Travis SP**, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. *Gut* 1996; **38**: 905-910 [PMID: 8984031 DOI: 10.1136/gut.38.6.905]

34 **Lindgren SC**, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. *Eur J Gastroenterol Hepatol* 1998; **10**: 831-835 [PMID: 9831403]

35 **Ananthakrishnan AN**, McGinley EL, Binion DG, Saeian K. Simple score to identify colectomy risk in ulcerative colitis hospitalizations. *Inflamm Bowel Dis* 2010; **16**: 1532-1540 [PMID: 20091926 DOI: 10.1002/ibd.21225]

36 **Markel TA**, Lou DC, Pfefferkorn M, Scherer LR, West K, Rouse T, Engum S, Ladd A, Rescorla FJ, Billmire DF. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis. *Surgery* 2008; **144**: 540-545; discussion 545-547 [PMID: 18847637 DOI: 10.1016/j.surg.2008.07.005]

37 **Mor IJ**, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. *Dis Colon Rectum* 2008; **51**: 1202-1207; discussion 1202-1210 [PMID: 18536964 DOI: 10.1007/s10350-008-9364-7]

38 **Roberts SE**, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. *BMJ* 2007; **335**: 1033 [PMID: 17977817 DOI: 10.1136/bmj.39345. 714039.55]

39 **Pellino G**, Sciaudone G, Candilio G, Canonico S, Selvaggi F. Rectosigmoid stump washout as an alternative to permanent mucous fistula in patients undergoing subtotal colectomy for ulcerative colitis in emergency settings. *BMC Surg* 2012; **12** Suppl 1: S31 [PMID: 23173990 DOI: 10.1186/1471-2482-12-S1-S31]

40 **Brady RR**, Collie MH, Ho GT, Bartolo DC, Wilson RG, Dunlop MG. Outcomes of the rectal remnant following colectomy for ulcera­tive colitis. *Colorectal Dis* 2008; **10**: 144-150 [PMID: 17302914]

41 **Fazio VW**, Kiran RP, Remzi FH, Coffey JC, Heneghan HM, Kirat HT, Manilich E, Shen B, Martin ST. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. *Ann Surg* 2013; **257**: 679-685 [PMID: 23299522 DOI: 10.1097/SLA. 0b013e31827d99a2]

42 **Wong NY**, Eu KW. A defunctioning ileostomy does not prevent clinical anastomotic leak after a low anterior resection: a pro­spective, comparative study. *Dis Colon Rectum* 2005; **48**: 2076-2079 [PMID: 16086220 DOI: 10.1007/s10350-005-0146-1]

43 **Sagar PM**, Taylor BA. Pelvic ileal reservoirs: the options. *Br J Surg* 1994; **81**: 325-332 [PMID: 8173895 DOI: 10.1002/bjs.1800810304]

44 **Shannon A**, Eng K, Kay M, Blanchard S, Wyllie R, Mahajan L, Worley S, Lavery I, Fazio V. Long-term follow up of ileal pouch anal anastomosis in a large cohort of pediatric and young adult patients with ulcerative colitis. *J Pediatr Surg* 2016; **51**: 1181-1186 [PMID: 26876089 DOI: 10.1016/j.jpedsurg.2015.12.012]

45 **Kirat HT**, Remzi FH, Kiran RP, Fazio VW. Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anasto­mosis in 3,109 patients. *Surgery* 2009; **146**: 723-729; discussion 729-730 [PMID: 19789032 DOI: 10.1016/j.surg.2009.06.041]

46 **Joo M**, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. *Am J Surg Pathol* 2010; **34**: 689-696 [PMID: 20410806 DOI: 10.1097/PAS.0b013e 3181db84cd]

47 **Scoglio D**, Ahmed Ali U, Fichera A. Surgical treatment of ulcera­tive colitis: ileorectal vs ileal pouch-anal anastomosis. *World J Gastro­enterol* 2014; **20**: 13211-13218 [PMID: 25309058 DOI: 10.3748/wjg.v20.i37.13211]

48 **Bikhchandani J**, Polites SF, Wagie AE, Habermann EB, Cima RR. National trends of 3- versus 2-stage restorative proctocolectomy for chronic ulcerative colitis. *Dis Colon Rectum* 2015; **58**: 199-204 [PMID: 25585078 DOI: 10.1097/DCR.0000000000000282]

49 **Zittan E**, Wong-Chong N, Ma GW, McLeod RS, Silverberg MS, Cohen Z. Modified Two-stage Ileal Pouch-Anal Anastomosis Results in Lower Rate of Anastomotic Leak Compared with Traditional Two-stage Surgery for Ulcerative Colitis. *J Crohns Colitis* 2016; **10**: 766-772 [PMID: 26951468 DOI: 10.1093/ecco-jcc/jjw069]

50 **Swenson BR**, Hollenbeak CS, Poritz LS, Koltun WA. Modified two-stage ileal pouch-anal anastomosis: equivalent outcomes with less resource utilization. *Dis Colon Rectum* 2005; **48**: 256-261 [PMID: 15711857 DOI: 10.1007/s10350-004-0848-9]

51 **Park KT**, Tsai R, Perez F, Cipriano LE, Bass D, Garber AM. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis. *Ann Surg* 2012; **256**: 117-124 [PMID: 22270693 DOI: 10.1097/SLA.0b013e3182445321]

52 **Watanabe K**, Funayama Y, Fukushima K, Shibata C, Takahashi K, Sasaki I. Hand-assisted laparoscopic vs. open subtotal colectomy for severe ulcerative colitis. *Dis Colon Rectum* 2009; **52**: 640-645 [PMID: 19404068 DOI: 10.1007/DCR.0b013e31819d47b5]

53 **Messenger DE**, Mihailovic D, MacRae HM, O’Connor BI, Victor JC, McLeod RS. Subtotal colectomy in severe ulcerative and Crohn’s colitis: what benefit does the laparoscopic approach confer? *Dis Colon Rectum* 2014; **57**: 1349-1357 [PMID: 25379999 DOI: 10.1097/DCR.0000000000000238]

54 **Gu J**, Stocchi L, Remzi FH, Kiran RP. Total abdominal colectomy for severe ulcerative colitis: does the laparoscopic approach really have benefit? *Surg Endosc* 2014; **28**: 617-625 [PMID: 24196546 DOI: 10.1007/s00464-013-3218-7]

55 **Meagher AP**, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. *Br J Surg* 1998; **85**: 800-803 [PMID: 9667712]

56 **Dafnis G**. Early and late surgical outcomes of ileal pouch-anal anastomosis within a defined population in Sweden. *Eur J Gastroenterol Hepatol* 2016; **28**: 842-849 [PMID: 26945126 DOI: 10.1097/MEG.0000000000000618]

57 **Nordenvall C**, Myrelid P, Ekbom A, Bottai M, Smedby KE, Olén O, Nilsson PJ. Probability, rate and timing of reconstructive surgery following colectomy for inflammatory bowel disease in Sweden: a population-based cohort study. *Colorectal Dis* 2015; **17**: 882-890 [PMID: 25885419 DOI: 10.1111/codi.12978]

58 **Murphy PB**, Khot Z, Vogt KN, Ott M, Dubois L. Quality of Life After Total Proctocolectomy With Ileostomy or IPAA: A Systematic Review. *Dis Colon Rectum* 2015; **58**: 899-908 [PMID: 26252853 DOI: 10.1097/DCR.0000000000000418]

Figure Legends

****

**Figure 1 Algorithm for treatment of acute severe ulcerative colitis.** UC: Ulcerative colitis; TAC: Total abdominal colectomy; IPAA: Ileal pouch-anal anastomosis; CBC: Complete blood count; CMP: Comprehensive metabolic panel; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein.

Footnotes

Manuscript source:Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: United States

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

Conflict-of-interest statement:We have no conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Peer-review started:April 5, 2016

First decision:may 23, 2016

Article in press: August 1, 2016

**P- Reviewer**: Madnani MA, Matowicka-Karna J **S- Editor**:Gong ZM **L- Editor**: A **E- Editor**:Li D